article

Immuno-oncology In-Depth Focus 2020

Posted: 26 May 2020 | | No comments yet

This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.











To read this in-depth focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Berkeley Lights, Genscript

Articles in this in-depth focus:

  • Triplet immuno-oncology drug combinations – the future of treating multiple cancers
    The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno‑oncology treatment paradigm in advanced malignancies with high unmet need.
  • Neoantigens: presenting new vaccine opportunities in immuno-oncology
    Neoantigens have gained much interest in recent years, mainly due to their ability to illicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
Send this to a friend